Today's board moves wrap includes Stephen Pearce, Malcolm Norris, Todd Ross, David Wheeler, Rudolf Tieleman, Kian Tan, Gabriel Chiappini, Anna Sloboda, Matt Callahan, Stephen Dennis, Richard Gibb, Bradley Marwood and Eduardo Robaina.
Our board moves wrap includes Jeremy Robinson, Matt Freedman, Michelle Roth, Bruce McFadzean, Mohit Kaushal, Matt Callahan, Simon Linge, and Bruce Munro.
Climate technology company Rumin8 has raised $US12 million in a funding round led by the Bill Gates-founded Breakthrough Energy Ventures and supported by Andrew and Nicola Forrest.
A Perth-based pharmaceutical founded by 40under40 winner Matt Callahan has acquired its first product in a bid to manoeuvre from research and development status to revenue-generating.
Matt Callahan has re-joined the board of Botanix Pharmaceuticals as an executive director following the decision by Robert Towner to step down as non-executive director.
Medicinal cannabis research company Emerald Clinics has boosted its management team with the appointment of Michael Winlo as chief executive, ahead of an expected IPO later this year.
Botanix Pharmaceuticals has appointed Vince Ippolito as its president in the US, and subject to shareholder approval, he will also assume the role of executive chairman for the company.
A carefully managed five-year incubation process for new Perth company Respirion Pharmaceuticals has resulted in one of the largest funding deals for Western Australia's biotech sector.
Two local biotech companies have announced capital raisings today, with Botanix Pharmaceuticals tapping investors for $8 million, while Roto-Gro International has boosted its coffers with a $4.5 million raising.
Medical dermatology company Botanix Pharmaceuticals has raised $15 million through a strongly supported share placement, with the proceeds set to be spent on developing its lead product for acne.
Shares in medical dermatology company Botanix Pharmaceuticals, led by Perth-based chairman Graham Griffiths and executive director Matt Callahan, have jumped more than 20 per cent today after the company announced successful results from an acne patient study.
Biotech Botanix Pharmaceuticals has raised $7.4 million in a placement of new shares to help it fund the further development of its dermatology products that contain a synthetic form of the cannabis compound, cannabidiol.
Medical dermatology company Botanix Pharmaceuticals has enjoyed healthy gains on its first day of trading on the ASX, after completing a reverse takeover of Bone Medical.
Perth's tight-knit angel investment community is growing more comfortable with soft tech plays, but there are calls for more investment in the ‘trickier' tech.
Venture capital managers Rob Newman and Matt Callahan have completed a major restructuring and expansion of their Perth business, which has about $60 million under management.
